AU2018400751B2 - Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof - Google Patents

Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof Download PDF

Info

Publication number
AU2018400751B2
AU2018400751B2 AU2018400751A AU2018400751A AU2018400751B2 AU 2018400751 B2 AU2018400751 B2 AU 2018400751B2 AU 2018400751 A AU2018400751 A AU 2018400751A AU 2018400751 A AU2018400751 A AU 2018400751A AU 2018400751 B2 AU2018400751 B2 AU 2018400751B2
Authority
AU
Australia
Prior art keywords
polysaccharide
pneumoniae
carrier protein
conjugates
crm197
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018400751A
Other languages
English (en)
Other versions
AU2018400751A1 (en
Inventor
Chitrananda Abeygunawardana
Yadong Adam CUI
Jian He
Michael J. Kosinski
Patrick Mchugh
Luwy MUSEY
Julie M. Skinner
William J. Smith
Michael Albert Winters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2018400751A1 publication Critical patent/AU2018400751A1/en
Application granted granted Critical
Publication of AU2018400751B2 publication Critical patent/AU2018400751B2/en
Priority to AU2022209360A priority Critical patent/AU2022209360B2/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Amend patent request/document other than specification (104) Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
AU2018400751A 2017-12-06 2018-12-04 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof Active AU2018400751B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022209360A AU2022209360B2 (en) 2017-12-06 2022-07-30 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595388P 2017-12-06 2017-12-06
US62/595,388 2017-12-06
PCT/US2018/063709 WO2019139692A2 (en) 2017-12-06 2018-12-04 Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022209360A Division AU2022209360B2 (en) 2017-12-06 2022-07-30 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2018400751A1 AU2018400751A1 (en) 2020-06-18
AU2018400751B2 true AU2018400751B2 (en) 2022-07-21

Family

ID=66334525

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018400751A Active AU2018400751B2 (en) 2017-12-06 2018-12-04 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2022209360A Active AU2022209360B2 (en) 2017-12-06 2022-07-30 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022209360A Active AU2022209360B2 (en) 2017-12-06 2022-07-30 Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Country Status (27)

Country Link
US (5) US11116828B2 (enExample)
EP (1) EP3720483B1 (enExample)
JP (4) JP7369123B2 (enExample)
KR (3) KR102686858B1 (enExample)
CN (2) CN117982633A (enExample)
AR (2) AR114154A1 (enExample)
AU (2) AU2018400751B2 (enExample)
BR (1) BR112020011414B8 (enExample)
CA (1) CA3084436A1 (enExample)
CL (1) CL2020001478A1 (enExample)
CO (1) CO2020006882A2 (enExample)
CR (2) CR20250169A (enExample)
EA (1) EA202091382A1 (enExample)
EC (1) ECSP20032085A (enExample)
GE (1) GEP20227420B (enExample)
IL (1) IL274954B (enExample)
JO (1) JOP20200141A1 (enExample)
MA (2) MA51049A (enExample)
MX (2) MX2020005779A (enExample)
NI (1) NI202000040A (enExample)
NZ (1) NZ765694A (enExample)
PE (1) PE20201338A1 (enExample)
PH (1) PH12020550891A1 (enExample)
SG (1) SG11202005255PA (enExample)
TW (1) TWI725359B (enExample)
UA (1) UA128603C2 (enExample)
WO (1) WO2019139692A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3096783T3 (da) * 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3576784B1 (en) 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
MX2019009867A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
BR112020004396A8 (pt) * 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
JP7438102B2 (ja) * 2017-09-07 2024-02-26 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
MX2020005779A (es) * 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
WO2020121159A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR20220042378A (ko) 2019-07-31 2022-04-05 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
EP4090364A4 (en) * 2020-01-17 2024-02-21 Inventprise, Inc. MULTIVALENT STREPTOCOCCAL VACCINES
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
GB2616690B (en) * 2021-09-04 2024-06-05 Serum Institute Of India Pvt Ltd Method for monitoring stability of polysaccharide-protein conjugate vaccines
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
AU2024271872A1 (en) 2023-05-18 2025-12-18 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
US20250255948A1 (en) 2024-02-14 2025-08-14 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccines and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
JPH10504842A (ja) 1995-06-06 1998-05-12 ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体免疫原性構築物
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
KR19980067137A (ko) 1997-01-31 1998-10-15 박원훈 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EP2281891A3 (en) 2000-06-20 2011-08-17 ID Biomedical Corporation Streptococcus antigens
WO2002000249A2 (en) 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
EP2258842A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2003901717A0 (en) 2003-04-10 2003-05-01 Western Sydney Area Health Service Identification of streptococcus pneumoniae serotypes
DE102004017696A1 (de) 2004-04-10 2005-10-27 Vorwerk & Co. Interholding Gmbh Bodenpflegegerät mit einer rotierbaren Bürste
BRPI0510659A (pt) 2004-06-04 2007-12-04 Pharmexa Inc indução de uma resposta imunológica contra polissacarìdeos de streptococcus pneumoniae
EP1828230A2 (en) 2004-12-16 2007-09-05 Stichting Top Institute Food and Nutrition Novel efficient process for production of capsular polysaccharides of pathogenic gram-positive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram-positive bacteria
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT3466982T (pt) 2005-04-08 2020-07-24 Wyeth Llc Separação de contaminantes do polissacárido de streptococcus pneumoniae por manipulação do ph
EP4005595A1 (en) * 2005-04-08 2022-06-01 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7764278B2 (en) 2005-06-30 2010-07-27 Seiko Epson Corporation Integrated circuit device and electronic instrument
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
JP5285431B2 (ja) 2005-12-28 2013-09-11 ザ ユーエイビー リサーチ ファウンデイション 肺炎球菌血清型
CA2635208C (en) 2005-12-28 2018-03-20 The Uab Research Foundation Streptococcus pneumonia having a capsular polysaccharide repeating unit {>2)glucose 1(1>3) glucose 2 (1>3) rhamnose (1>3)ribitol (5>phosphate}
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
DK2056871T3 (en) 2006-08-07 2018-02-26 Harvard College PROTEIN MATRIX VACCINES AND PROCEDURES FOR THE PREPARATION AND ADMINISTRATION OF SUCH VACCINES
JP5260531B2 (ja) 2006-10-10 2013-08-14 ワイス・エルエルシー 肺炎連鎖球菌３型多糖体の精製
RU2516340C2 (ru) 2007-03-23 2014-05-20 Вайет Ускоренный способ очистки для получения капсульных полисахаридов streptococcus pneumoniae
EA201391788A1 (ru) 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
MX346071B (es) 2008-12-18 2017-03-02 Wyeth Llc Método para controlar el peso molecular del polisacárido de streptococcus pneumoniae utilizando dióxido de carbono.
ES2666698T3 (es) 2008-12-18 2018-05-07 Wyeth Llc Procedimiento de control del peso molecular del polisacárido del serotipo 19A de Streptococcus pneumoniae
CN101590224A (zh) 2009-06-30 2009-12-02 广州精达医学科技有限公司 高效14价肺炎球菌结合疫苗
AU2010292195A1 (en) 2009-09-09 2012-03-15 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
MX2012013664A (es) 2010-06-04 2013-01-24 Wyeth Llc Formulaciones de vacuna.
RU2013131795A (ru) 2010-12-10 2015-01-20 Мерк Шарп Энд Домэ Корп. Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций
CN102068690A (zh) 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
DK2709656T3 (da) 2011-05-18 2019-06-24 Matrivax Inc Proteinmatrix-vaccinesammensætninger omfattende polykationer
US20140193876A1 (en) 2011-06-13 2014-07-10 Aaron R. Goerke Methods of purification of native or mutant forms of diphtheria toxin
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN103623401A (zh) 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
CN103656632B (zh) 2012-09-24 2016-01-13 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖组合物、其制备方法及应用
CN103656631B (zh) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
SI2935299T1 (sl) 2012-12-20 2019-12-31 Pfizer Inc. Postopek glikokonjugacije
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104069488A (zh) 2013-03-29 2014-10-01 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
HRP20211288T1 (hr) 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
DK3096783T3 (da) 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
EP3302542A4 (en) 2015-06-08 2019-04-10 Serum Institute Of India Private Limited METHOD FOR IMPROVING ADSORPTION OF POLYSACCHARIDE PROTEIN CONJUGATES AND POLYVALENT VACCINE FORMULATION THEREOF
ES2857474T3 (es) 2015-06-23 2021-09-29 Biological E Ltd Vacuna conjugada neumocócica multivalente
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
KR20250058066A (ko) 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
RU2021135165A (ru) 2015-11-17 2021-12-29 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
CN105999254A (zh) 2016-06-27 2016-10-12 北京智飞绿竹生物制药有限公司 含2型和12f血清型的15价肺炎球菌结合物组合疫苗
WO2018009906A1 (en) 2016-07-08 2018-01-11 President And Fellows Of Harvard College Whole cell-protein conjugates and methods of making the same
CN109845298B (zh) 2016-07-27 2021-12-28 夏普株式会社 使用系统信息值标签的无线电信方法和装置
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
JOP20190038B1 (ar) 2016-09-06 2023-09-17 Lg Chemical Ltd تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته
CN109789198B (zh) 2016-09-30 2024-08-16 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
KR20180043122A (ko) 2016-10-19 2018-04-27 동국대학교 산학협력단 신규링커를 통한 폐렴구균 다당류-단백질 접합체 백신 및 이의 용도
WO2018080213A1 (ko) 2016-10-28 2018-05-03 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
CN108144056A (zh) 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 多价肺炎球菌多糖结合疫苗及其制备方法
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
EP3576784B1 (en) 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
WO2018156465A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
MX2019009867A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
US20200061542A1 (en) 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
EP4656650A2 (en) 2017-02-24 2025-12-03 Merck Sharp & Dohme LLC Pneumococcal conjugate vaccine formulations
WO2018169303A1 (ko) 2017-03-15 2018-09-20 주식회사 엘지화학 다가 폐렴구균 백신 조성물
CN107929728A (zh) 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 一种肺炎球菌蛋白疫苗及其制备方法
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
CN109091668A (zh) 2017-06-20 2018-12-28 浙江博和瑞达生物科技有限公司 16价肺炎链球菌结合疫苗组合物
CN110996992A (zh) 2017-08-16 2020-04-10 默沙东公司 肺炎球菌缀合物疫苗制剂
MX394768B (es) 2017-09-07 2025-03-21 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.
EP3678694A4 (en) 2017-09-07 2021-10-20 Merck Sharp & Dohme Corp. METHOD FOR FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
BR112020004396A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
JP7438102B2 (ja) 2017-09-07 2024-02-26 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
JP2021501144A (ja) 2017-10-25 2021-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アジュバントワクチン
MX2020005779A (es) * 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
JP2019118051A (ja) 2017-12-27 2019-07-18 株式会社デンソー 表示処理装置
CN108159408A (zh) 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
CN108245674A (zh) 2018-01-18 2018-07-06 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合物组合疫苗的处方及其制备方法
CN108079286B (zh) 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
EP3749358A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
WO2019170068A1 (zh) 2018-03-05 2019-09-12 武汉博沃生物科技有限公司 一种肺炎链球菌疫苗及其制备方法
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US20210236384A1 (en) 2018-05-07 2021-08-05 Meissner Filtration Products Lyophilization Bag
CN108339115B (zh) 2018-05-11 2020-07-10 武汉博沃生物科技有限公司 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法
WO2019220304A1 (en) 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
EP3801469A4 (en) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. CRITICAL LYOSPHERE REAGENTS KIT
CN108524926B (zh) 2018-06-29 2021-06-29 康希诺生物股份公司 一种多价肺炎球菌结合疫苗的制剂组合及其应用
WO2020009462A1 (ko) 2018-07-06 2020-01-09 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 폐렴구균에 의한 질환 예방 백신
CN108543066A (zh) 2018-07-17 2018-09-18 成都安特金生物技术有限公司 一种24价肺炎球菌多糖疫苗及其鉴别方法
KR102884263B1 (ko) 2018-07-21 2025-11-10 바이오로지칼 이 리미티드 방부제 시스템을 포함하는 백신 제제
KR102879391B1 (ko) 2018-09-23 2025-10-30 바이오로지칼 이 리미티드 스트렙토코쿠스 뉴모니아에의 정제된 협막 다당류
CN113194987B (zh) 2018-10-12 2024-11-08 生物E有限公司 多价肺炎球菌多糖-蛋白缀合的疫苗
CN109336989B (zh) 2018-10-22 2022-05-13 北京智飞绿竹生物制药有限公司 一种通过粘度控制制备肺炎球菌荚膜多糖的方法
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020152706A1 (en) 2019-01-21 2020-07-30 Biological E Limited Multivalent pneumococcal conjugate vaccine compositions
WO2020157772A1 (en) 2019-01-28 2020-08-06 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
CN109771640A (zh) 2019-02-28 2019-05-21 北京智飞绿竹生物制药有限公司 多价肺炎球菌结合疫苗
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN114025790A (zh) 2019-06-05 2022-02-08 默沙东公司 免疫原性血清型35b肺炎球菌多糖-蛋白缀合物和用于制备其的缀合方法
KR20220016964A (ko) 2019-06-05 2022-02-10 머크 샤프 앤드 돔 코포레이션 에스. 뉴모니아에 혈청형 29에 대해 보호하는 면역원성 조성물을 사용하여 환자를 치료하는 방법
CN110302375A (zh) 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
CN110365663A (zh) * 2019-06-28 2019-10-22 北京淇瑀信息科技有限公司 一种隔离集群之间的访问方法、装置及电子设备
WO2021010798A1 (ko) 2019-07-18 2021-01-21 (주)셀트리온 다가 폐렴구균 다당류-단백질 접합체를 포함하는 면역원성 조성물
KR20220042378A (ko) 2019-07-31 2022-04-05 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
CN111821432B (zh) 2020-08-05 2022-10-18 北京智飞绿竹生物制药有限公司 一种多价肺炎球菌结合疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof

Also Published As

Publication number Publication date
AR126443A2 (es) 2023-10-11
CA3084436A1 (en) 2019-07-18
AU2018400751A1 (en) 2020-06-18
KR20230130153A (ko) 2023-09-11
US12097250B2 (en) 2024-09-24
US20240398925A1 (en) 2024-12-05
IL274954A (en) 2020-07-30
CR20200245A (es) 2020-07-17
ECSP20032085A (es) 2020-08-31
CL2020001478A1 (es) 2020-12-18
BR112020011414A2 (pt) 2020-12-01
SG11202005255PA (en) 2020-07-29
KR102686858B1 (ko) 2024-07-19
TW201925458A (zh) 2019-07-01
CN117982633A (zh) 2024-05-07
US20240108711A1 (en) 2024-04-04
KR20230006024A (ko) 2023-01-10
US20210177957A1 (en) 2021-06-17
MX2020005779A (es) 2020-10-28
WO2019139692A3 (en) 2019-08-15
BR112020011414B1 (pt) 2022-09-27
TWI725359B (zh) 2021-04-21
KR102481327B1 (ko) 2022-12-23
JP7587666B2 (ja) 2024-11-20
US20210379174A1 (en) 2021-12-09
UA128603C2 (uk) 2024-08-28
AU2022209360A1 (en) 2022-09-29
GEP20227420B (en) 2022-10-10
BR112020011414B8 (pt) 2023-01-31
KR102573200B1 (ko) 2023-08-31
JP2025024036A (ja) 2025-02-19
JP7458682B2 (ja) 2024-04-01
CO2020006882A2 (es) 2020-06-19
AR114154A1 (es) 2020-07-29
PE20201338A1 (es) 2020-11-25
MA51048A (fr) 2021-03-17
CN111683678A (zh) 2020-09-18
NZ765694A (en) 2024-03-22
NI202000040A (es) 2020-09-24
JOP20200141A1 (ar) 2022-10-30
CR20250169A (es) 2025-05-26
IL274954B (en) 2021-10-31
EP3720483B1 (en) 2025-11-19
JP7369123B2 (ja) 2023-10-25
AU2022209360B2 (en) 2024-11-14
MX2024006606A (es) 2024-06-12
JP2024023417A (ja) 2024-02-21
US20190192648A1 (en) 2019-06-27
BR122021023687A2 (enExample) 2020-12-01
EP3720483A2 (en) 2020-10-14
JP2021505589A (ja) 2021-02-18
KR20200096266A (ko) 2020-08-11
US11850278B2 (en) 2023-12-26
US11116828B2 (en) 2021-09-14
WO2019139692A2 (en) 2019-07-18
BR122021023687A8 (pt) 2023-02-07
PH12020550891A1 (en) 2021-04-12
EA202091382A1 (ru) 2021-01-15
MA51049A (fr) 2020-10-14
JP2022130553A (ja) 2022-09-06
CN111683678B (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
AU2022209360B2 (en) Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12016914B2 (en) Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EA043489B1 (ru) Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
BR122021023687B1 (pt) Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: CAPVAXIVE PNEUMOCOCCAL

Filing date: 20250205

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: CAPVAXIVE PNEUMOCOCCAL

Filing date: 20250205

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: CAPVAXIVE PNEUMOCOCCAL

Filing date: 20250205

Extension date: 20400205